Cytheris, a privately held French clinical-stage biopharmaceutical company focused on treating lymphopenia driven diseases, has appointed Damian Marron as chief executive.
Marron was previously chief executive at Trophos. His first task at Cytheris will be to guide the acceleration of the development of its leading compound CYT107 (glycosylated r-hIL-7).
‘I am delighted to be taking on responsibility for leading Cytheris in the next stage of its development,’ said Marron.
‘Cytheris has already generated a significant body of clinical and pre-clinical evidence demonstrating the ability of CYT107 to reverse lymphopenia and restore immune function.’
Marron brings more than 25 years of biotechnology and industry experience to his new role, especially from his last four years as ceo with Trophos. Prior to Trophos, he was executive vice president corporate development at NicOx, where he was responsible for the establishment of major collaborations with Merck and Co and Pfizer and participated in financing rounds raising in excess of €175m. Previously, he held various business development and operational roles at 3M Pharmaceuticals, Orphan Europe, Rhone-Poulenc-Rorer and Glaxo.
